CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 14,340 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $20.60, for a total transaction of $295,404.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of CytomX Therapeutics, Inc. (NASDAQ CTMX) traded down $0.24 during trading hours on Tuesday, reaching $20.55. 389,015 shares of the company’s stock traded hands, compared to its average volume of 278,100. CytomX Therapeutics, Inc. has a 1 year low of $10.40 and a 1 year high of $24.67.

A number of large investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its stake in CytomX Therapeutics by 1.3% in the second quarter. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company’s stock valued at $343,000 after purchasing an additional 292 shares in the last quarter. Legal & General Group Plc increased its position in shares of CytomX Therapeutics by 28.6% during the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,434 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of CytomX Therapeutics by 39.4% during the second quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 4,622 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of CytomX Therapeutics by 5.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 100,091 shares of the biotechnology company’s stock worth $1,729,000 after acquiring an additional 4,959 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of CytomX Therapeutics by 18.6% during the third quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock worth $670,000 after acquiring an additional 5,800 shares in the last quarter. 63.18% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently weighed in on the stock. Cowen restated a “buy” rating on shares of CytomX Therapeutics in a report on Tuesday, August 8th. ValuEngine lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Nomura increased their price objective on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Bank of America restated a “buy” rating and issued a $30.00 price objective (up from $28.00) on shares of CytomX Therapeutics in a report on Wednesday, August 9th. Finally, Cantor Fitzgerald assumed coverage on shares of CytomX Therapeutics in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price objective on the stock. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $31.88.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/05/sean-a-mccarthy-sells-14340-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.